• 1
    Mariani AJ, Mariani MC, Macchioni C, et al. The significance of adult hematuria: 1000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol. 1989; 141: 350-355.
  • 2
    Johnson EK, Daignault S, Zhang Y, et al. Patterns of hematuria referral to urologists: does a gender disparity exist? Urology. 2008; 72: 498-502.
  • 3
    Grossfeld GD, Litwin MS, Wolf JSJr, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy—part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology. 2001; 57: 604-610.
  • 4
    Wallace DM, Bryan RT, Dunn JA, et al. Delay and survival in bladder cancer. BJU Int. 2002; 89: 868-878.
  • 5
    Gulliford MC, Petruckevitch A, Burney PG. Survival with bladder cancer, evaluation of delay in treatment, type of surgeon, and modality of treatment. BMJ. 1991; 303: 437-440.
  • 6
    Fahmy NM, Mahmud S, Aprikian AG. Delay in the surgical treatment of bladder cancer and survival: systematic review of the literature. Eur Urol. 2006; 50: 1176-1182.
  • 7
    Mahmud SM, Fong B, Fahmy N, et al. Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. J Urol. 2006; 175: 78-83.
  • 8
    Sanchez-Ortiz RF, Huang WC, Mick R, et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol. 2003; 169: 110-115.
  • 9
    May M, Nitzke T, Helke C, et al. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder. Scand J Urol Nephrol. 2004; 38: 231-235.
  • 10
    Chang SS, Hassan JM, Cookson MS, et al. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol. 2003; 170: 1085-1087.
  • 11
    Hara I, Miyake H, Hara S, et al. Optimal timing of radical cystectomy for patients with invasive transitional cell carcinoma of the bladder. Jpn J Clin Oncol. 2002; 32: 14-18.
  • 12
    Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19: 666-675.
  • 13
    Lotan Y, Svatek RS, Malats N. Screening for bladder cancer: a perspective. World J Urol. 2008; 26: 13-18.
  • 14
    Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40( suppl): IV-3-IV-18.
  • 15
    National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program. Bethesda, Md: National Cancer Institute; 2006. Available at: Accessed January 30, 2009.
  • 16
    Lee CT, Madii R, Daignault S, et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J Urol. 2006; 175: 1262-1267.
  • 17
    Bach PB, Guadagnoli E, Schrag D, et al. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002; 40( suppl): IV-19-IV-25.
  • 18
    Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  • 19
    Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267.
  • 20
    Diez-Roux AV, Merkin SS, Arnett D, et al. Neighborhood of residence and incidence of coronary heart disease. N Engl J Med. 2001; 345: 99-106.
  • 21
    Kleinbaum DG, Klein M. Evaluating the proportional hazards assumption. In: Gail M, Krickeberg K, Samet J, et al, eds. Survival Analysis: A Self-Learning Text. New York: Springer Science & Business Media, Inc.; 1996: 129-166.
  • 22
    Lee CT, Dunn RL, Ingold C, et al. Early stage bladder cancer surveillance does not improve survival if high-risk patients are permitted to progress to muscle invasion. Urology. 2007; 69: 1068-1072.
  • 23
    Radford MJ, Foody JM. How do observational studies expand the evidence base for therapy? JAMA. 2001; 286: 1228-1230.
  • 24
    Heney NM, Nocks BN, Daly JJ, et al. Ta and T1 bladder cancer: location, recurrence and progression. Br J Urol. 1982; 54: 152-157.
  • 25
    Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004; 291: 2441-2447.
  • 26
    Anderson RT, Sorlie P, Backlund E, et al. Mortality effects of community socioeconomic status. Epidemiology. 1997; 8: 42-47.
  • 27
    Lotan Y, Gupta A, Shariat SF, et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005; 23: 6533-6539.
  • 28
    Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995; 87: 1603-1612.
  • 29
    Penson DF, Albertsen PC, Nelson PS, et al. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst. 2001; 93: 1822-1823.
  • 30
    Weinstock MA, Reynes JF. Validation of cause-of-death certification for outpatient cancers: the contrasting cases of melanoma and mycosis fungoides. Am J Epidemiol. 1998; 148: 1184-1186.